Dimethyl Sulfoxide
Apexbio Technology LLC DMXAA (Vadimezan) 117570-53-3 10mM (in 1mL DMSO)
DMXAA (Vadimezan AS-1404) is a tumor vascular disrupting and apoptosis-inducing agent functioning primarily through inhibition of DT-diaphorase (DTD) It acts by suppressing DTD enzymatic activity showing an IC50 of approximately 62 5 M Additionally DMXAA inhibits various kinases notably VEGFR2 disrupting endothelial cells and blood vessel formation to induce tumor cell apoptosis and vascular necrosis Experimentally DMXAA demonstrates activity in murine tumor models including induction of apoptosis in endothelial cells and tumor vasculature promoting necrosis and tumor regression Therefore DMXAA is commonly used in oncology research focused on anti-angiogenesis and tumor vascular disruption mechanisms
Medchemexpress LLC XMU-MP-9 ,10 mM 1 mL in DMSO Solution
XMU-MP-9 is a bifunctional compound that binds to the C2 domain of Nedd4-1 and the allosteric site of K-Ras. XMU-MP-9 enhances the interaction between Nedd4-1 and K-Ras, induces conformational changes in the Nedd4-1/K-Ras complex, promotes the ubiquitination and degradation of multiple K-Ras mutants, and inhibits the proliferation of cells carrying K-Ras mutants. XMU-MP-9 can be used in cancer research.
Apexbio Technology LLC Amantadine HCl 665-66-7 10mM (in 1mL DMSO)
Amantadine Hydrochloride a dopamine receptor agonist is primarily employed as a research tool in neuroscience and antiviral studies It exerts its antiparkinsonian effects by promoting dopamine release and inhibiting dopamine reuptake consequently enhancing dopaminergic neurotransmission As an antiviral agent amantadine hydrochloride inhibits influenza A virus replication through blockade of the viral matrix protein M2 ion channel In cell-based assays amantadine hydrochloride demonstrates inhibitory activity against influenza A viruses with reported IC50 values typically ranging between 0 3 to 1 5 M depending on assay conditions and viral strains Researchers commonly utilize this compound to investigate neurological pathways associated with Parkinson s disease viral infection mechanisms and drug resistance phenomena
Apexbio Technology LLC HOAt 39968-33-7 10mM (in 1mL DMSO)
HOAt (1-Hydroxy-7-azabenzotriazole) is a peptide coupling reagent frequently employed in peptide synthesis for the activation of carboxylic groups Structurally HOAt serves as an activating additive that forms reactive intermediates facilitating amide bond formation while mitigating side reactions such as racemization As reported in experimental peptide coupling studies combining HOAt with diisopropylcarbodiimide (DIC) promotes coupling reactions with improved retention of stereochemical integrity relative to traditional coupling systems utilizing other benzotriazole derivatives HOAt is thus commonly used both in segment coupling and stepwise solid-phase peptide assembly methodologies aimed at synthesizing peptides requiring minimal epimerization
Apexbio Technology LLC GSK-923295 1088965-37-0 10mM (in 1mL DMSO)
GSK-923295 (CAS 1088965-37-0) is a highly potent inhibitor targeting the centromere-associated protein E (CENP-E) a kinesin motor protein essential for proper chromosome alignment and progression from metaphase to anaphase during cell division By blocking microtubule-stimulated ATPase activity of CENP-E GSK-923295 stabilizes an ATP-bound intermediate resulting in significantly reduced enzymatic function (IC50 3 2 nM) In cellular models GSK-923295 induces mitotic arrest with morphological changes similar to CENP-E knockdown In mouse xenograft models using Colo205 colon carcinoma cells administration of GSK-923295 leads to tumor growth inhibition and increased apoptosis supporting its utility in cancer research
Apexbio Technology LLC BYL-719 1217486-61-7 10mM (in 1mL DMSO)
BYL-719 (CAS 1217486-61-7) is a selective inhibitor of PI3K demonstrating minimal activity against PI3K or isoforms Through targeting PI3K an essential node frequently dysregulated via PIK3CA mutations in various cancers BYL-719 effectively disrupts downstream proliferative signaling In biochemical assays BYL-719 shows potent inhibition of PI3K with an IC50 of 5 nM Preclinical evaluations indicate dose-dependent antitumor efficacy in xenograft tumor models and proliferation arrest and apoptosis induction in multiple myeloma cell lines exhibiting PIK3CA overexpression Clinically initial studies reveal manageable safety profiles and preliminary antitumor responses notably in PIK3CA-mutant malignancies supporting continued exploration in oncology research settings
Apexbio Technology LLC GZD824 1421783-64-3 10mM (in 1mL DMSO)
GZD824 (CAS 1421783-64-3) is an orally bioavailable inhibitor of the Bcr-Abl kinase a fusion protein exhibiting tyrosine kinase activity involved in regulating cell cycle progression and genomic stability GZD824 binds competitively to the ATP-binding site of Abl kinase effectively inhibiting the phosphorylation and activation of both wild-type (WT) and resistant mutant forms (e g T315I E255K G250E Q252H H396P M351T and Y253F) GZD824 demonstrates sub-nanomolar IC50 values and substantially reduces proliferation in Bcr-Abl-expressing Ba/F3 cell models Preclinical studies in mouse xenograft leukemia models show GZD824 suppresses tumor growth highlighting its potential applicability in research into resistance mechanisms and targeted leukemia therapies
Apexbio Technology LLC LCL161 1005342-46-0 10mM (in 1mL DMSO)
LCL161 (CAS 1005342-46-0) is a small-molecule antagonist targeting inhibitor of apoptosis (IAP) proteins specifically designed as a mimetic of the endogenous second mitochondria-derived activator of caspase (SMAC) LCL161 binds to and inhibits XIAP and cIAP1/2 proteins frequently overexpressed in malignant cells It demonstrates antiproliferative activity in vitro against selected hepatocellular carcinoma cell lines (Hep3B PLC5) and hematologic cancer models (ALL) with IC50 values in the micromolar range In in vivo tumor xenograft studies oral administration of LCL161 has led to significant growth delays across various malignancies including osteosarcoma and glioblastoma Its combination with AAVP-delivered TNF- results in synergistic antitumor effects indicating its utility in oncology research
Apexbio Technology LLC Thioridazine HCl 130-61-0 10mM (in 1mL DMSO)
Thioridazine HCl is a pharmacological inhibitor targeting dopamine receptor subtypes D2 and D4 as well as a calcium channel blocker It modulates dopaminergic neurotransmission by interfering with receptor-mediated signaling and reduces intracellular calcium influx via calcium channel inhibition (IC50 approximately 1 0 M) Thioridazine is frequently utilized in research contexts involving dopaminergic signaling pathways calcium-related cellular processes and investigations of pharmacological sensitivity shifts following prolonged receptor modulation Specifically it is employed experimentally to examine receptor-mediated cardiovascular responses such as hypotension and to assess alterations in dopamine receptor responsiveness induced by chronic exposure regimens
Medchemexpress LLC Encorafenib (Synonyms: LGX818) 10 mM * 1 mL in DMSO
Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM).
Medchemexpress LLC Ro4929097 10 Mm / 1 Ml In Dmso | HY-11102-10MM/1ML IN DMSO
Ro4929097 10 Mm / 1 Ml In Dmso
Apexbio Technology LLC Reparixin 266359-83-5 10mM (in 1mL DMSO)
Reparixin (CAS 266359-83-5) is a noncompetitive allosteric inhibitor of chemokine receptors CXCR1 and CXCR2 which are seven-transmembrane G-protein coupled receptors involved notably in acute inflammatory responses Reparixin specifically disrupts CXCR1/2-mediated neutrophil recruitment and migration without affecting other receptor pathways In murine ischemia-reperfusion injury models Reparixin administration significantly inhibits neutrophil influx and associated inflammation-related tissue damage Thus Reparixin serves as a valuable research tool for investigating CXCR-dependent inflammatory mechanisms and evaluating therapeutic potentials in conditions such as acute lung injury and spinal cord damage
Apexbio Technology LLC ORY-1001 1431326-61-2 10mM (in 1mL DMSO)
ORY-1001 is a selective inhibitor targeting the lysine-specific histone demethylase KDM1A (also known as LSD1) an FAD-dependent amine oxidase enzyme responsible for the removal of histone methylation marks particularly dimethylation of histone H3 lysine 4 (H3K4me2) By inhibiting KDM1A ORY-1001 promotes accumulation of H3K4me2 at gene targets and induces cellular differentiation in acute myeloid leukemia (AML) cell models In vitro assays demonstrated dose- and time-dependent increases in H3K4me2 and expression of differentiation markers in treated AML cells ORY-1001 exhibited oral bioavailability in animal xenograft models reducing tumor growth at low daily doses This molecule serves as a valuable research tool in epigenetics oncology pharmacology and studies regarding AML differentiation pathways with ongoing evaluation in early-phase clinical trials